<code id='0356013C03'></code><style id='0356013C03'></style>
    • <acronym id='0356013C03'></acronym>
      <center id='0356013C03'><center id='0356013C03'><tfoot id='0356013C03'></tfoot></center><abbr id='0356013C03'><dir id='0356013C03'><tfoot id='0356013C03'></tfoot><noframes id='0356013C03'>

    • <optgroup id='0356013C03'><strike id='0356013C03'><sup id='0356013C03'></sup></strike><code id='0356013C03'></code></optgroup>
        1. <b id='0356013C03'><label id='0356013C03'><select id='0356013C03'><dt id='0356013C03'><span id='0356013C03'></span></dt></select></label></b><u id='0356013C03'></u>
          <i id='0356013C03'><strike id='0356013C03'><tt id='0356013C03'><pre id='0356013C03'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:fashion    - browse:99
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore